Granata Bio Secures $15M Series A+ to Advance Reproductive Health Innovation

  • Granata Bio announces completion of a $15M Series A+ funding round supported by existing investors.
  • The investment will bolster its reproductive health pipeline and explore innovative fertility solutions.

Granata Bio Corporation, a biopharma company addressing the global infertility medication market valued at $3.6 billion, has successfully closed a $15 million Series A+ funding round. This round was exclusively backed by existing investors, including Gedeon Richter, CooperSurgical, Amboy Street Ventures, and other strategic partners. The company has now raised over $30 million in total funding.

The new funding will accelerate the advancement of Granata Bio’s existing pipeline and enable the exploration of new assets in reproductive health. The company aims to strengthen its leadership in this critical therapeutic area by developing innovative solutions for fertility patients.

Evan Sussman, CEO of Granata Bio, expressed his gratitude for the unwavering support of their investors, stating, “We are grateful for the continued confidence and commitment shown by our existing investors, especially our strategic partners who are leaders in women’s health, Gedeon Richter and CooperSurgical. With this new funding, we are well-positioned to accelerate the development of our current and future pipeline.”

The funding round was managed with representation from Mintz, highlighting Granata Bio’s ongoing commitment to enhancing fertility treatment access and outcomes for patients worldwide. The company’s strategic focus on reproductive health continues to shape its efforts to address a growing market need.

Sign up to the free weekly newsletter for all the latest biotech news, resources and podcasts.  Register here

Experience the future of contract manufacturing

Join us at CDMO Live, 7-8 May 2025 in Rotterdam for an exclusive live event dedicated to contract manufacturing partnerships. Apply for your ticket.

UPCOMING EVENT

New from PharmaSource, CDMO Live (Rotterdam, May 7-8, 2025) brings together biopharma’s manufacturing leaders to optimise their outsourcing strategy.

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.